Source:http://linkedlifedata.com/resource/pubmed/id/12586619
Switch to
| Predicate | Object |
|---|---|
| rdf:type | |
| lifeskim:mentions | |
| pubmed:issue |
10
|
| pubmed:dateCreated |
2003-5-6
|
| pubmed:abstractText |
P57KIP2 is a cyclin-dependent kinase inhibitor silenced in a variety of human malignancies. DNA methylation of a region surrounding the transcription start site of p57KIP2 was found in acute lymphocytic leukemia (ALL)-derived cell lines. Methylation of this region correlated with gene silencing, and treatment of methylated/silenced cell lines with 5-aza-2'-deoxycytidine resulted in gene re-expression. P57KIP2 was methylated in 31 (50%) of 63 patients with newly diagnosed ALL, and in 11 (52%) of 21 patients with relapsed ALL. In 5 of them (25%), methylation was acquired at relapse. No association was observed between methylation of p57KIP2 alone and clinical-biologic characteristics studied, including overall survival (OS) or disease-free survival. Methylation of multiple genes in a cell-cycle regulatory pathway composed of p73, p15, and p57KIP2 occurred in 22% of Philadelphia chromosome (Ph)-negative patients. Ph-negative patients with methylation of 2 or 3 genes of this pathway had a significantly worse median OS compared with those with methylation of 0 or 1 gene (50 vs 467 weeks, respectively; P =.02). Our results indicate that p57KIP2 is frequently methylated in adult patients with ALL, and that inactivation of a pathway composed of p73, p15, and p57KIP2 predicts for poor prognosis in Ph-negative patients.
|
| pubmed:language |
eng
|
| pubmed:journal | |
| pubmed:citationSubset |
AIM
|
| pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/CDKN1C protein, human,
http://linkedlifedata.com/resource/pubmed/chemical/Cyclin-Dependent Kinase Inhibitor...,
http://linkedlifedata.com/resource/pubmed/chemical/Cyclin-Dependent Kinases,
http://linkedlifedata.com/resource/pubmed/chemical/Enzyme Inhibitors,
http://linkedlifedata.com/resource/pubmed/chemical/Nuclear Proteins
|
| pubmed:status |
MEDLINE
|
| pubmed:month |
May
|
| pubmed:issn |
0006-4971
|
| pubmed:author |
pubmed-author:DanielSophiaS,
pubmed-author:Garcia-ManeroGuillermoG,
pubmed-author:ImaiKohzohK,
pubmed-author:IssaJean-Pierre JJP,
pubmed-author:KantarjianHagop MHM,
pubmed-author:KondoYutakaY,
pubmed-author:ObataToshiroT,
pubmed-author:PierceSherryS,
pubmed-author:ShenLanLanL,
pubmed-author:ToyotaMinoruM
|
| pubmed:issnType |
Print
|
| pubmed:day |
15
|
| pubmed:volume |
101
|
| pubmed:owner |
NLM
|
| pubmed:authorsComplete |
Y
|
| pubmed:pagination |
4131-6
|
| pubmed:dateRevised |
2009-11-19
|
| pubmed:meshHeading |
pubmed-meshheading:12586619-Adolescent,
pubmed-meshheading:12586619-Adult,
pubmed-meshheading:12586619-Aged,
pubmed-meshheading:12586619-Cell Cycle,
pubmed-meshheading:12586619-Cyclin-Dependent Kinase Inhibitor p57,
pubmed-meshheading:12586619-Cyclin-Dependent Kinases,
pubmed-meshheading:12586619-DNA Methylation,
pubmed-meshheading:12586619-Enzyme Inhibitors,
pubmed-meshheading:12586619-Female,
pubmed-meshheading:12586619-Humans,
pubmed-meshheading:12586619-Jurkat Cells,
pubmed-meshheading:12586619-Leukemia-Lymphoma, Adult T-Cell,
pubmed-meshheading:12586619-Male,
pubmed-meshheading:12586619-Middle Aged,
pubmed-meshheading:12586619-Nuclear Proteins,
pubmed-meshheading:12586619-Prognosis,
pubmed-meshheading:12586619-Survival Analysis,
pubmed-meshheading:12586619-Time Factors,
pubmed-meshheading:12586619-Tumor Cells, Cultured
|
| pubmed:year |
2003
|
| pubmed:articleTitle |
Aberrant DNA methylation of p57KIP2 identifies a cell-cycle regulatory pathway with prognostic impact in adult acute lymphocytic leukemia.
|
| pubmed:affiliation |
Department of Leukemia, University of Texas M.D. Anderson Cancer Center, Houston, TX 77030, USA.
|
| pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't
|